Erratum for

• Exploring the potential of low-dose sulfasalazine in stable coronary artery disease patients: randomized, double-blind, placebo-controlled study.

  Vohra K, Krishan P, Varma S, Kalra HS. Vohra K, et al. Eur Heart J Cardiovasc Pharmacother. 2015 Oct;1(4):214-6. doi: 10.1093/ehjcvp/pvv021. Epub 2015 Apr 21. Eur Heart J Cardiovasc Pharmacother. 2015. PMID: 27532443 No abstract available.
• Meta-analysis of admission hyperglycaemia in acute myocardial infarction patients treated with primary angioplasty: a cause or a marker of mortality?

  Singh K, Hibbert B, Singh B, Carson K, Premaratne M, Le May M, Chong AY, Arstall M, So D. Singh K, et al. Eur Heart J Cardiovasc Pharmacother. 2015 Oct;1(4):220-8. doi: 10.1093/ehjcvp/pvv023. Epub 2015 Apr 29. Eur Heart J Cardiovasc Pharmacother. 2015. PMID: 27532445 Review.
• Glycemic control and acute coronary syndrome: the debate continues.

  Marfella R, Paolisso G. Marfella R, et al. Eur Heart J Cardiovasc Pharmacother. 2015 Oct;1(4):229-31. doi: 10.1093/ehjcvp/pvv027. Epub 2015 Jun 1. Eur Heart J Cardiovasc Pharmacother. 2015. PMID: 27532446 No abstract available.
• Potassium levels in acute myocardial infarction: definitely worth paying attention to.

  Dixon DL, Abbate A. Dixon DL, et al. Eur Heart J Cardiovasc Pharmacother. 2015 Oct;1(4):252-3. doi: 10.1093/ehjcvp/pvv029. Epub 2015 Jun 18. Eur Heart J Cardiovasc Pharmacother. 2015. PMID: 27532448 No abstract available.
• Cardiovascular pharmacology: a look back and a glimpse into the future.

  Braunwald E. Braunwald E. Eur Heart J Cardiovasc Pharmacother. 2015 Jan;1(1):7-9. doi: 10.1093/ehjcvp/pvu002. Epub 2015 Jan 1. Eur Heart J Cardiovasc Pharmacother. 2015. PMID: 27533957 No abstract available.
• Editorial Comment for the "Risk of Thrombocytopenia with Glycoprotein IIb/IIIa Inhibitors across Drugs and Patient Populations: a Meta-Analysis of 29 Large Placebo-Controlled Randomized Trials". Thrombocytopenia as an important complication with the use of antithrombotic agents.

  Goto S, Goto S. Goto S, et al. Eur Heart J Cardiovasc Pharmacother. 2015 Jan;1(1):29-30. doi: 10.1093/ehjcvp/pvu014. Epub 2015 Jan 1. Eur Heart J Cardiovasc Pharmacother. 2015. PMID: 27533961 No abstract available.
• Back to the future: the crucial role of clinical registries in the era of randomized controlled trials for identifying the optimal medical therapy of heart failure.

  Pelliccia F, Rosano GM. Pelliccia F, et al. Eur Heart J Cardiovasc Pharmacother. 2015 Jan;1(1):37-8. doi: 10.1093/ehjcvp/pvu015. Epub 2015 Jan 1. Eur Heart J Cardiovasc Pharmacother. 2015. PMID: 27533963 No abstract available.
• Renal denervation: back to reality, finally!

  Taddei S, Bruno RM. Taddei S, et al. Eur Heart J Cardiovasc Pharmacother. 2015 Jan;1(1):57. doi: 10.1093/ehjcvp/pvu013. Epub 2015 Jan 1. Eur Heart J Cardiovasc Pharmacother. 2015. PMID: 27533967 No abstract available.
• What is the need for another new journal?

  Opie LH. Opie LH. Eur Heart J Cardiovasc Pharmacother. 2015 Apr;1(2):74-5. doi: 10.1093/ehjcvp/pvu012. Epub 2015 Feb 19. Eur Heart J Cardiovasc Pharmacother. 2015. PMID: 27533971 No abstract available.
• Stroke prevention in atrial fibrillation: changing concepts.

  Lip GY. Lip GY. Eur Heart J Cardiovasc Pharmacother. 2015 Apr;1(2):76-9. doi: 10.1093/ehjcvp/pvu003. Epub 2015 Mar 20. Eur Heart J Cardiovasc Pharmacother. 2015. PMID: 27533972 No abstract available.
• How European Society of Cardiology guidelines are made.

  Zamorano JL. Zamorano JL. Eur Heart J Cardiovasc Pharmacother. 2015 Apr;1(2):82. doi: 10.1093/ehjcvp/pvu019. Epub 2015 Feb 19. Eur Heart J Cardiovasc Pharmacother. 2015. PMID: 27533974 No abstract available.
• Editorial comment on 'A novel approach indirectly comparing benefit: risk across oral antithrombotic therapies in patients with atrial fibrillation'. Are the evidences of current dose-adjusted anticoagulation with warfarin stroke prevention for patients with atrial fibrillation sufficient enough to compare with newly developed non-vitamin K oral anticoagulants?

  Goto S, Goto S. Goto S, et al. Eur Heart J Cardiovasc Pharmacother. 2015 Apr;1(2):83-5. doi: 10.1093/ehjcvp/pvu017. Epub 2015 Feb 19. Eur Heart J Cardiovasc Pharmacother. 2015. PMID: 27533975 No abstract available.
• Risk of thrombocytopenia with glycoprotein IIb/IIIa inhibitors across drugs and patient populations: a meta-analysis of 29 large placebo-controlled randomized trials.

  Wessler JD, Giugliano RP. Wessler JD, et al. Eur Heart J Cardiovasc Pharmacother. 2015 Apr;1(2):97-106. doi: 10.1093/ehjcvp/pvu008. Epub 2015 Feb 19. Eur Heart J Cardiovasc Pharmacother. 2015. PMID: 27533978 Review.
• Non-steroidal anti-inflammatory drugs and incident atrial fibrillation.

  Proietti M, Lip GY. Proietti M, et al. Eur Heart J Cardiovasc Pharmacother. 2015 Apr;1(2):115-6. doi: 10.1093/ehjcvp/pvv007. Epub 2015 Mar 10. Eur Heart J Cardiovasc Pharmacother. 2015. PMID: 27533980 No abstract available.
• Cardiorenal protection during chronic renin-angiotensin-aldosterone system suppression: evidences and caveats.

  Ruiz-Hurtado G, Ruilope LM. Ruiz-Hurtado G, et al. Eur Heart J Cardiovasc Pharmacother. 2015 Apr;1(2):126-31. doi: 10.1093/ehjcvp/pvu023. Epub 2015 Mar 20. Eur Heart J Cardiovasc Pharmacother. 2015. PMID: 27533982 Review.
• Simple decision-making between a vitamin K antagonist and a non-vitamin K antagonist oral anticoagulant: using the SAMe-TT2R2 score.

  Proietti M, Lip GY. Proietti M, et al. Eur Heart J Cardiovasc Pharmacother. 2015 Jul;1(3):150-2. doi: 10.1093/ehjcvp/pvv012. Epub 2015 Mar 4. Eur Heart J Cardiovasc Pharmacother. 2015. PMID: 27533987 No abstract available.
• Closing the information gap between clinical and postmarketing trials: the case of dabigatran.

  Rolden HJ, Grutters JP, van der Wilt GJ, Maas AH. Rolden HJ, et al. Eur Heart J Cardiovasc Pharmacother. 2015 Jul;1(3):153-6. doi: 10.1093/ehjcvp/pvv020. Epub 2015 Apr 17. Eur Heart J Cardiovasc Pharmacother. 2015. PMID: 27533988 No abstract available.
• Did referral patterns for coronary angiography change in Europe? What can we learn from Denmark?

  Koller L, Niessner A. Koller L, et al. Eur Heart J Cardiovasc Pharmacother. 2015 Jul;1(3):166-7. doi: 10.1093/ehjcvp/pvv013. Epub 2015 Mar 4. Eur Heart J Cardiovasc Pharmacother. 2015. PMID: 27533990 No abstract available.
• Medical management: the dark side of acute coronary syndromes.

  Bueno H. Bueno H. Eur Heart J Cardiovasc Pharmacother. 2015 Jul;1(3):179-81. doi: 10.1093/ehjcvp/pvv017. Epub 2015 Mar 27. Eur Heart J Cardiovasc Pharmacother. 2015. PMID: 27533992 No abstract available.
• Synergistic effects of cardiac resynchronization therapy and drug up-titration in heart failure: is this enough?

  Volpe M, Francia P. Volpe M, et al. Eur Heart J Cardiovasc Pharmacother. 2015 Jul;1(3):189-90. doi: 10.1093/ehjcvp/pvv022. Epub 2015 Apr 29. Eur Heart J Cardiovasc Pharmacother. 2015. PMID: 27533994 No abstract available.